<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02162784</url>
  </required_header>
  <id_info>
    <org_study_id>INTB012</org_study_id>
    <secondary_id>INTB012</secondary_id>
    <nct_id>NCT02162784</nct_id>
  </id_info>
  <brief_title>Efficacy Study of SYN006 HFA MDI in Asthma Patients</brief_title>
  <official_title>An Open-Label, Randomized, Cross-Over Study to Evaluate the Dose Response of SYN006 HFA MDI in Asthma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intech Biopharm Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intech Biopharm Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the dose response of SYN006 HFA MDI, which is a&#xD;
      combination drug product of budesonide and procaterol hydrochloride, in asthma patients.&#xD;
      Patients with mild to moderate asthma will be recruited. There will be two study medication&#xD;
      administered in this study. The investigational medication is SYN006 (Budesonide/Procaterol&#xD;
      hydrochloride, 180 mcg/10 mcg per inhalation) and the active comparative medication is&#xD;
      Ventolin (Salbutamol sulfate 100 mcg per inhalation). The study medication will be&#xD;
      administered by oral inhalation with the supervision of the investigator or a qualified&#xD;
      staff.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Three treatments will be administered in a patient:&#xD;
&#xD;
        -  A. Two inhalations of Ventolin 100 mcg,&#xD;
&#xD;
        -  B. One inhalation of SYN006 180/10 mcg,&#xD;
&#xD;
        -  C. Two inhalations of SYN006 180/10 mcg.&#xD;
&#xD;
      Patients will be received the study treatment according to one of the six treatment sequences&#xD;
      according to the randomization schedule:&#xD;
&#xD;
        1. A-B-C,&#xD;
&#xD;
        2. B-A-C,&#xD;
&#xD;
        3. C-A-B,&#xD;
&#xD;
        4. C-B-A,&#xD;
&#xD;
        5. A-C-B,&#xD;
&#xD;
        6. B-C-A.&#xD;
&#xD;
      The efficacy endpoint is&#xD;
&#xD;
        -  The change in Forced Expiratory Volume in 1 second (FEV1) within 6 hours.&#xD;
&#xD;
        -  The change in Peak Expiratory Flow Rate (PEFR) within 6 hours.&#xD;
&#xD;
        -  The change in Force Vital Capacity (FVC) within 6 hours.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The variation of study medications by the area under curve of FEV1 from 0 to 120 minutes (AUC0-120min ) after inhalation.</measure>
    <time_frame>5, 20, 40, 60, 90, 120 minutes, 4, and 6 hours after the inhalation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change in Forced Expiratory Volume in 1 second (FEV1) of study medication.</measure>
    <time_frame>5, 20, 40, 60, 90, 120 minutes, 4, and 6 hours after the inhalation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in Peak Expiratory Flow Rate (PEFR) of study medication.</measure>
    <time_frame>5, 20, 40, 60, 90, 120 minutes, 4, and 6 hours after the inhalation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in Forced Vital Capacity (FVC) of study medication.</measure>
    <time_frame>5, 20, 40, 60, 90, 120 minutes, 4, and 6 hours after the inhalation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The variation of study medications by the area under curve of PEFR from 0 to 120 minutes (AUC0-120min ) after inhalation.</measure>
    <time_frame>5, 20, 40, 60, 90, 120 minutes, 4, and 6 hours after the inhalation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The variation of study medications by the area under curve of FVC from 0 to 120 minutes (AUC0-120min ) after inhalation.</measure>
    <time_frame>5, 20, 40, 60, 90, 120 minutes, 4, and 6 hours after the inhalation</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events, vital signs, abnormal ECG outcome.</measure>
    <time_frame>5, 20, 40, 60, 90, 120 minutes, 4, and 6 hours after the inhalation</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Budesonide/procaterol 180/10mcg X1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HFA MDI, oral inhalation, 180/10mcg, one puff</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Budesonide/Procaterol, 180/10mcg X2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HFA MDI, oral inhalation, two puffs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Albuterol HFA MDI 100 mcg X2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HFA MDI, oral inhalation, 100mcg, two puffs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide/Procaterol, 180/10mcg X1</intervention_name>
    <description>one puff</description>
    <arm_group_label>Budesonide/procaterol 180/10mcg X1</arm_group_label>
    <other_name>Synbitide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide/procaterol 180/10 mcg X 2</intervention_name>
    <description>2 puffs</description>
    <arm_group_label>Budesonide/Procaterol, 180/10mcg X2</arm_group_label>
    <other_name>Synbitide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albuterol HFA MDI 100mcg X2</intervention_name>
    <description>HFA MDI, 100mcg, 2 puffs</description>
    <arm_group_label>Albuterol HFA MDI 100 mcg X2</arm_group_label>
    <other_name>Ventolin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patient aged &gt;= 16 years old&#xD;
&#xD;
          -  History of FEV1 &gt;=12% and 200 ml increase after inhalation of short-acting beta&#xD;
             2-agonist;&#xD;
&#xD;
          -  Pre-bronchodilator FEV1 &gt; 60% and &lt; 90% of predicted normal value at enrollment;&#xD;
&#xD;
          -  Ability to inhale correctly through MDI inhaler&#xD;
&#xD;
          -  Written informed consent obtained.&#xD;
&#xD;
          -  Diagnosis of mild to moderate persistent asthma according to GINA with a documented&#xD;
             history of at least 6 months duration.&#xD;
&#xD;
        Mild Persistent:&#xD;
&#xD;
          1. Symptoms more than once a week but less than once a day&#xD;
&#xD;
          2. Nocturnal symptoms more than twice a month&#xD;
&#xD;
          3. Exacerbations may affect activity and sleep&#xD;
&#xD;
          4. FEV1 or PEF &gt;= 80% predicted&#xD;
&#xD;
          5. PEF or FEV1 variability &lt; 20 - 30%&#xD;
&#xD;
        Moderate Persistent:&#xD;
&#xD;
          1. Symptoms daily&#xD;
&#xD;
          2. Nocturnal symptoms more than once a week&#xD;
&#xD;
          3. Exacerbations may affect activity and sleep&#xD;
&#xD;
          4. Daily use of inhaled short-acting beta2-agonist&#xD;
&#xD;
          5. FEV1 or PEF &gt; 60% - &lt; 80% predicted&#xD;
&#xD;
          6. PEF or FEV1 variability &gt; 30%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently uncontrolled asthma according to GINA guideline;&#xD;
&#xD;
          -  Allergy, sensitivity or intolerance to study drugs and/or study drug formulation&#xD;
             ingredients;&#xD;
&#xD;
          -  Inability to carry out pulmonary function testing;&#xD;
&#xD;
          -  Severe asthma associated with reduced lung function;&#xD;
&#xD;
          -  Clinically significant or unstable concurrent diseases: uncontrolled hyperthyroidism,&#xD;
             significant hepatic impairment, poorly controlled pulmonary disease (tuberculosis,&#xD;
             active mycotic infection of the lung), gastrointestinal (e.g., active peptic ulcer),&#xD;
             neurological or haematological autoimmune diseases;&#xD;
&#xD;
          -  Abnormal ECG at enrollment;&#xD;
&#xD;
          -  History of near-fatal asthma and/or admission intensive care unit because of asthma;&#xD;
&#xD;
          -  History or current evidence of heart failure, coronary artery disease, myocardial&#xD;
             infarction, severe hypertension, or cardiac arrhythmias;&#xD;
&#xD;
          -  Percutaneous transluminal coronary angioplasty (PTCA) or coronary artery by-pass graft&#xD;
             (CABG) during the previous 6 months at enrollment;&#xD;
&#xD;
          -  Hospitalization for asthma during the past 3 months at enrollment;&#xD;
&#xD;
          -  Evidence of severe asthma exacerbation or symptomatic infection of the airways in the&#xD;
             previous 3 months at enrollment;&#xD;
&#xD;
          -  Current smokers or recent (less than one year) ex-smokers, defined as smoking at least&#xD;
             10 pack/years;&#xD;
&#xD;
          -  History of alcohol or drug abuse;&#xD;
&#xD;
          -  Pregnant or lactating females or not able to exclude pregnancy during the study&#xD;
             period;&#xD;
&#xD;
          -  Patients unlikely to comply with the protocol or unable to understand the nature,&#xD;
             scope and possible consequences of the study;&#xD;
&#xD;
          -  Patients who received any investigational new drug within the last 3 months at&#xD;
             enrollment;&#xD;
&#xD;
          -  Patients who have been previously enrolled in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chung Shan Medical University Hospital</name>
      <address>
        <city>TaiChung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>June 11, 2014</study_first_submitted>
  <study_first_submitted_qc>June 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2014</study_first_posted>
  <last_update_submitted>June 2, 2015</last_update_submitted>
  <last_update_submitted_qc>June 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Procaterol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

